Efficacy and safety of tenecteplase administration in extended time window for acute ischemic stroke: An updated meta-analysis of randomized controlled trials
Эффективность и безопасность применения тенектеплазы в расширенном временно́м окне при остром ишемическом инсульте: обновлённый метаанализ рандомизированных контролируемых исследований
2025-05-03
SCID: 54.1/ph9akb9m
Discuss with AI
acute ischemic strokeextended time windowrandomized controlled trialssymptomatic intracranial hemorrhagetenecteplase
Figures from the paper
Abstract (AI)
BACKGROUND: Data regarding the efficacy and safety of tenecteplase (TNK) in patients with acute ischemic stroke (AIS) who present outside the standard treatment window are limited. This study aims to evaluate the role of TNK at a dose of 0.25 mg/kg, in treating AIS patients in an extended time window. METHODS: Searches were performed up to February 15, 2025 in PubMed, Embase, and Cochrane Library to include randomized-controlled trials (RCTs) comparing TNK (0.25 mg/kg) to no thrombolysis in AIS patients presenting after 4.5 hours of symptom onset or wake-up AIS. The primary efficacy outcomes included a 3-month excellent functional outcome (mRS ⩽1), and a good functional outcome (mRS ⩽2). Secondary safety outcomes assessed included symptomatic intracranial hemorrhage (sICH), any ICH, and 3-month all-cause death. A random-effects model was used to calculate summary estimates. RESULTS: 6 RCTs were included (n = 1,955 patients) in the meta-analysis. The pooled analysis demonstrated a significantly improved excellent functional outcome on 90 days (OR = 1.35, 95 % CI: 1.12 to 1.64) with TNK administration compared to control. No statistically significant association was observed for the two groups regarding good functional outcome (OR = 1.16, 95 % CI: 0.94 to 1.44), all-cause death (OR = 1.11, 95 % CI: 0.82 to 1.49), sICH (OR = 1.79, 95 % CI: 0.94 to 3.39), and any ICH (OR = 1.21, 95 % CI: 0.96 to 1.53). CONCLUSION: TNK administration in an extended time window for AIS patients leads to favorable neurological outcomes with a good safety profile.
Key Findings
1
An updated meta-analysis included 6 randomized controlled trials involving 1,955 acute ischemic stroke patients treated beyond 4.5 hours or after wake-up stroke.
2
No statistically significant differences were found for all-cause mortality, symptomatic intracranial hemorrhage, or any intracranial hemorrhage.
3
Tenecteplase at 0.25 mg/kg significantly increased the likelihood of excellent 90-day functional outcome (mRS ≤1) versus no thrombolysis (OR 1.35, 95% CI 1.12–1.64).
4
Tenecteplase was not significantly associated with good functional outcome defined as mRS ≤2 (OR 1.16, 95% CI 0.94–1.44).
5
The findings support favorable neurological outcomes and an overall good safety profile for tenecteplase in selected patients treated during an extended time window.
Research Object
Acute ischemic stroke patients presenting in an extended time window or with wake-up stroke, treated with 0.25 mg/kg tenecteplase
Research Subject
The efficacy and safety of tenecteplase, including functional outcomes, symptomatic and any intracranial hemorrhage, and all-cause mortality
Publication Details
Publication Date
2025-05-03
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest